Abstract 561: Discovery of a potential best-in-class anti-CD38 therapeutic utilizing Fc multimerization
Sign Up to like & getrecommendations! Published in 2019 at "Immunology"
DOI: 10.1158/1538-7445.am2019-561
Abstract: CD38 targeting antibodies are at different phases of clinical development, with daratumumab already approved as monotherapy and in combination with standards of care in multiple myeloma (MM). Anti-CD38 monoclonal antibodies (mAbs) induce tumor cell depletion… read more here.
Keywords: sifbody; multimerization; cd38; cell ... See more keywords